Insider Buying: FocalTherics (NASDAQ:FOCL) General Counsel Purchases $23,750.00 in Stock

FocalTherics (NASDAQ:FOCL) General Counsel Sanket Shah purchased 5,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, with a total value of $23,750.00. Following the completion of the purchase, the general counsel owned 72,500 shares of the company’s stock, valued at approximately $344,375. This represents a 7.41% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

FocalTherics Price Performance

FOCL stock opened at $4.76 on Monday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The stock’s 50-day moving average is $5.39. The company has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. FocalTherics has a 1 year low of $1.30 and a 1 year high of $6.40.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The firm had revenue of $13.20 million during the quarter. On average, analysts anticipate that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on FOCL shares. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday. Finally, Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.75.

Institutional Investors Weigh In On FocalTherics

A number of hedge funds and other institutional investors have recently bought and sold shares of FOCL. Leonteq Securities AG bought a new position in FocalTherics in the 4th quarter worth about $313,000. Kovack Advisors Inc. purchased a new stake in shares of FocalTherics in the fourth quarter worth about $53,000. Rock Springs Capital Management LP boosted its position in shares of FocalTherics by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after acquiring an additional 16,500 shares during the period. Flax Pond Capital LLC bought a new position in shares of FocalTherics in the fourth quarter valued at approximately $2,623,000. Finally, SmartHarvest Portfolios LLC purchased a new position in FocalTherics during the first quarter valued at approximately $38,000. Institutional investors own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.